Avid Bioservices Inc (CDMO)

[biopharm]

After reading this patent more closely....this "upstream" looks like it could be referring to Phosphatidylserine and now more interesting is the Epiontis collaboration with Peregrine and Turbachova laboratory

The below conference was just in June 2017 and I was surprised to see Epiontis there ....as they discuss secondary endpoints and now imagine those secondary endpoints coming Peregrine's way......also note JUNO presence

...
CHARACTERIZATION OF HUMAN TUMORS

9:00 Chairperson’s Opening Remarks
Travis Beckett, M.S., Scientist, Flow Cytometry Team Lead, Technology Research & Development, Juno Therapeutics
...
..
DETERMINANTS OF TUMOR-IMMUNE INTERACTION

1:40 Chairperson’s Remarks
Thomas Oliver Kleen, Ph.D., Executive Vice President, Immune Monitoring, Epiontis GmbH
..
..

2:20 Immuno-Oncology Trials - Next Generation Immune Monitoring Tools as a Way Forward
Thomas_KleenThomas Oliver Kleen, Ph.D., Executive Vice President, Immune Monitoring, Epiontis GmbH
Monitoring both systemic changes in the blood and intra-tumoral leukocyte subpopulations will be crucial for identifying potential early surrogate markers of immunotherapy treatment success, ultimately paving the way to acceptable secondary endpoints for future Immuno-Oncology trials. Logistics, sample requirements, stability of cells in blood samples and tissue and cost considerations often preclude the use of standard monitoring assays. Novel technologies allow precise and robust quantitation of immune cells in all human samples from only small amounts of blood or tissue.
...
..
http://www.worldpreclinicalcongress.com/Cell-analysis-immunotherapy/